AWH Aspira Women's Health: Market Capitalization to Book Value Ratio

Official company branding of Aspira Women's Health Inc (AWH)

Due to the humanitarian status of biomedicine, Aspira Women's Health operates within a stable geopolitical environment. Analyzing the company's price-to-book ratio on GURU.Markets, we note that the metric has settled at -0.53. The competitiveness of AWH is based on proprietary oncology diagnostic algorithms, while operational efficiency is achieved through cloud outsourcing of IT infrastructure and user support.

Aspira Women's Health Inc (AWH): Capitalization to Book Value Ratio from 07/04/2022 to 04/26/2025
Core merchandise of Aspira Women's Health, Inc.

Aspira Women's Health is scaling the commercial implementation of innovative oncology tests by expanding insurance coverage. This metric compares the current market value of the business with its net book value. This ratio determines the extent to which shares are overvalued relative to the company's tangible assets. The fundamental value of assets serves as a defensive barrier during market volatility. The trend of this parameter within the historical relationship between market capitalization and book value allows for an assessment of the investment's margin of safety.

Main competitors

A (Agilent Technologies) - Market Value to Book Value Ratio|questdiagnostics.com (DGX) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ILMN (Illumina)|Market-to-Book Ratio Exact Sciences Corp|Market Capitalization to Book Value Ratio PerkinElmer RVTY|Capitalization to Book Value Ratio Bio-Rad Corp (BIO)|Market Capitalization to Book Value Ratio NNNN (Anbio Biotechnology)|soterahealth.com - Market Capitalization to Book Value Ratio|QuidelOrtho Corporation (QDEL) - Market Value to Book Value Ratio|OPK - Capitalization to Book Value Ratio|CDNA: Market Capitalization to Book Value Ratio|MRVI (Maravai) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Fulgent Genetics, Inc.|Market Value to Book Value Ratio fluidigm.com (LAB)|Cytek Biosciences - Market Cap to Net Assets Ratio|Market-to-Book Ratio OSUR (OraSure Technologies, Inc.)|Market Value to Book Value Ratio XGN|Market Capitalization to Book Value MDxHealth, Inc. MDXH|Market Capitalization to Book Value Ratio LUCD (Lucid Diagnostics Inc.)|PRE: Market Capitalization to Book Value|imdxinc.com - Market Value to Book Value Ratio|Trinity Biotech (TRIB) - Market Capitalization to Book Value|PRPH (ProPhase) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio AIMD|CODX (Co-Diagnostics, Inc.) - Market Value to Book Value Ratio|Market Capitalization to Book Value HSCS (heartsciences.com)|Biomerica (BMRA) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Cardio Diagnostics Holdings Inc. CDIO|Market Capitalization to Book Value Ratio VRAX (Virax Biolabs Group Ltd)|BJDX: Market Capitalization to Book Value|Market Value to Book Value Ratio Accelerate Diagnostics AXDX|CENTOGENE (CNTG) - Market Value to Book Value|ENZ (Enzo Biochem Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fresh2 (FRES)|Genetic Technologies (GENE) - Market Cap to Net Assets Ratio|Market Value to Book Value 23andMe Inc ME|Psychemedics - Market Cap to Net Assets Ratio